1. Home
  2. OPRX vs RNA Comparison

OPRX vs RNA Comparison

Compare OPRX & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OptimizeRx Corporation

OPRX

OptimizeRx Corporation

N/A

Current Price

$7.68

Market Cap

167.1M

ML Signal

N/A

Logo Avidity Biosciences Inc.

RNA

Avidity Biosciences Inc.

N/A

Current Price

$7.58

Market Cap

141.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPRX
RNA
Founded
2006
2025
Country
United States
United States
Employees
105
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.1M
141.3M
IPO Year
2008
2025

Fundamental Metrics

Financial Performance
Metric
OPRX
RNA
Price
$7.68
$7.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$12.30
★ $22.00
AVG Volume (30 Days)
181.3K
★ 203.2K
Earning Date
11-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 124.55
N/A
EPS
★ N/A
N/A
Revenue
★ $109,429,000.00
N/A
Revenue This Year
N/A
$88.07
Revenue Next Year
$8.01
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 18.78
N/A
52 Week Low
$4.54
$7.49
52 Week High
$15.59
$73.06

Technical Indicators

Market Signals
Indicator
OPRX
RNA
Relative Strength Index (RSI) 37.22 34.12
Support Level $7.23 $7.56
Resistance Level $8.30 $8.50
Average True Range (ATR) 0.69 0.36
MACD -0.19 -0.02
Stochastic Oscillator 38.21 6.58

Price Performance

Historical Comparison
OPRX
RNA

About OPRX OptimizeRx Corporation

OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.

About RNA Avidity Biosciences Inc.

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Share on Social Networks: